|Project name: ||Shingles Immunisation Programme - there are 2 reports for this project: 2014, 2015 |
|Google search: ||Google search on project name (opens in new window) |
|Organisation: ||DOH (D12) - see all reports for this organisation |
|Report year: ||2014 (data is from Sept 2013) |
|Category: ||Transformation - see all reports for this category |
|Description: ||Background: Shingles is caused by the reactivation of the chicken pox virus in a person with a dormant chicken pox infection. It is not known what causes the virus to reactivate but this is usually associated with those with a suppressed or less effective immune systems. Shingles incidence is highest in older people as the incidence of shingles increases with age; in the UK it is estimated to be around 790 to 880 cases per 100,000 people, an estimated 30,000 cases of shingles per year for people aged 70 79 each year. In 2010, JCVI advised that a universal shingles programme should be implemented for people aged 70 years and up to 79 years inclusive if a licensed vaccine was available at a cost effective price. The Department of Health (DH) has a legal obligation, under the 2010 NHS Constitution, to offer new vaccines to the public that are recommended by JCVI and which are shown to be cost effective. Shingles vaccination will be introduced as part of the arrangements for delivering routine immunisations to adults. NHS England will be responsible for commissioning these services and will need to decide on the most appropriate arrangements for securing delivery as per the service specifications supplied by Public Health England (PHE).
Objective: The overarching objective of a shingles vaccination programme is the reduction of shingles and associated sequaelae in England.
Scope: The scope of the project is limited to England and includes all the elements required to successfully deliver a shingles vaccination and catch up programme.
Benefits: The programme will deliver: (1) sustained improvements in public health; (2) a reduction in burden on the NHS by reducing the need for treatment and (3) a cost effective health intervention.
Maturity: The Shingles vaccination will be introduced as part of the arrangements for delivering routine immunisations to adults. The indicative start date for the programme is 1 September 2013, with the vaccine being given alongside the seasonal flu vaccine for the routine 70 year old cohort. There will also be an annual catch-up programme offered to specified co-horts, commencing with 79 year olds in year 1 of the programme, 78 year olds in year 2, 77 year olds in year 3 etc. This pattern will continue until those eligible for the vaccine between 70 79 are offered the vaccine. This delivery model is based around current vaccine supply. The catch-up programme could potentially be implemented quicker if vaccine production increases from 2016 |
|DCA (RAG): ||Amber/Green |
|DCA text: ||Project delivered on time and within budget with NHS/Providers being experienced in the delivery of new immunisation programmes. There was a temporary delay with the supply of the shingles vaccine, Zostavax®, into the UK. Supply was resumed in December 2013. Preliminary data suggests, despite the interruption to vaccine supply, there is still good uptake in the identified cohorts. |
|Start date: ||2012-12-11 |
|End date: ||2013-11-01 |
|Schedule text: ||Project delivered on time. |
|Baseline: ||£51.30m |
|Forecast: ||£51.30m |
|Variance: ||0.00% |
|Variance text: ||There is no variance. |
|Whole Life Cost: ||£171.53m |
|WLCost text: ||No variance between the WLC budget and the WLC actual forecast. |
|Notes1: || |
|Notes2: || |
|Sourcefile: ||IPA_2014.csv |
All Projects (+dates)
All Projects (+costs)
Acknowledgement: GMPP data has been re-used under the Open Government Licence.